This post was written by Melanie Riehl BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 ...
This post was written by Melanie Riehl BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 ...
Pharmaceuticals led the sector, thanks in part to growing demand for GLP-1 obesity and diabetes drugs. Positive clinical trial readouts in large markets, such as oncology, were another tailwind.
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...
The Gazette on MSN47mOpinion
Brownstein: Scientist will give the skinny on Ozempic during symposium at McGillThe Corner Booth Dr. Patricia Brubaker has spent decades researching and speaking on studies relating to the development of ...
The line includes thoughtfully portioned meals that offer at least 20 grams of protein and contain essential nutrients such ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
While both berberine and Ozempic may lead to weight loss, they are very different things. It’s “inaccurate and misleading” to ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...
An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback